Reaktion #1452973
ord-2fff77945a5c4b8fa5dd9c7ccb6d8ce4
Reaktionsgleichung
1-[4-(5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-ylmethyl)-piperazin-1-yl]-2-hydroxy-propan-1-one
3-(4,4,5,5-tetramethyl-1,3,2,-dioxaborolan-2-yl)quinoline
→
106
Ausbeute 35.7%
(S)-2-hydroxy-1-(4-((7-morpholino-5-(quinolin-3-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propan-1-one
Ausbeute 35.7%
Edukte
Reagenzien
Keine
Reaktionsbedingungen
Detaillierte Bedingungen
See reaction.notes.procedure_details.
Aufarbeitung
- 1SonstigeThe product was purified by reverse phase HPLC
Vorschrift
1-[4-(5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-ylmethyl)-piperazin-1-yl]-2-hydroxy-propan-1-one (100 mg) was reacted with 72 mg of 3-(4,4,5,5-tetramethyl-1,3,2,-dioxaborolan-2-yl)quinoline via General Procedure A. The product was purified by reverse phase HPLC to yield 43.5 mg of 106. MS (Q1) 520.3 (M)+.